Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Atea Pharmaceuticals, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 111 | 1 | 127 | +17 |
| Shares | 57.0M | 4.23M | 60.1M | +7.32M (+13.9%) |
| Value | $203.5M | $15.1M | $322.8M | +$134.4M (+71.3%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (27)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (10)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Two Sigma Advisers, LP | 1,059,700 | $3.78M |
| Marshall Wace, LLP | 113,585 | $405.5K |
| Los Angeles Capital Management LLC | 77,304 | $252.8K |
| HRT Financial LP | 47,891 | $170.0K |
| Schonfeld Strategic Advisors LLC | 45,921 | $163.9K |
| Graham Capital Management, L.P. | 12,678 | $45.3K |
| SG Americas Securities, LLC | 10,742 | $38.0K |
| Amalgamated Bank | 2,233 | $8.00K |
| Daiwa Securities Group Inc. | 242 | $1.00K |
| SRS Capital Advisors, Inc. | 8 | $29 |
Not filed for Q1 2026 yet (1)
Institutions that held Atea Pharmaceuticals, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 4,227,110 | $15.1M |